Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia

Saved in:
Bibliographic Details
Published inBlood cancer journal (New York) Vol. 11; no. 2; pp. 25 - 6
Main Authors Maiti, Abhishek, DiNardo, Courtney D., Daver, Naval G., Rausch, Caitlin R., Ravandi, Farhad, Kadia, Tapan M., Pemmaraju, Naveen, Borthakur, Gautam, Bose, Prithviraj, Issa, Ghayas C., Short, Nicholas J., Yilmaz, Musa, Montalban-Bravo, Guillermo, Ferrajoli, Alessandra, Jabbour, Elias J., Jain, Nitin, Ohanian, Maro, Takahashi, Koichi, Thompson, Philip A., Loghavi, Sanam, Montalbano, Kathryn S., Pierce, Sherry, Wierda, William G., Kantarjian, Hagop M., Konopleva, Marina Y.
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 01.02.2021
Springer Nature B.V
Nature Publishing Group
Subjects
631/67/1990/283/1897
692/700/565/1436/2185
Adult
Aged
Antineoplastic Agents - therapeutic use
Biomedical and Life Sciences
Biomedicine
Bridged Bicyclo Compounds, Heterocyclic - therapeutic use
Cancer Research
Correspondence
Decitabine - therapeutic use
Female
fms-Like Tyrosine Kinase 3 - antagonists & inhibitors
fms-Like Tyrosine Kinase 3 - genetics
Hematology
Humans
Leukemia, Myeloid, Acute - drug therapy
Leukemia, Myeloid, Acute - genetics
Male
Middle Aged
Mutation - drug effects
Oncology
Protein Kinase Inhibitors - therapeutic use
Sulfonamides - therapeutic use
Treatment Outcome
Online AccessGet full text
ISSN2044-5385
2044-5385
DOI10.1038/s41408-021-00410-w

Cover

More Information
Bibliography:SourceType-Scholarly Journals-1
ObjectType-Correspondence-1
content type line 14
ObjectType-Article-2
ObjectType-Feature-1
ObjectType-Correspondence-3
content type line 23
ISSN:2044-5385
2044-5385
DOI:10.1038/s41408-021-00410-w